Should ropeginterferon become SoC for all patients with low-risk PV?

During the 25th Congress of the European Hematology Association (EHA), the MPN Hub spoke to Tiziano Barbui, L'ospedale Papa Giovanni XXIII, Bergamo, IT. We asked: Should ropeginterferon become standard of care for all patients with low-risk polycythemia vera (PV)?

Hematocrit control is vital in patients with PV, but is phlebotomy necessary to maintain hematocrit target levels? The monopegylated IFNα-2b, ropeginterferon, may reduce the need for phlebotomy. Results from the randomized phase II study comparing ropeginterferon with phlebotomy for the treatment of low-risk PV will be presented at this year's EHA meeting.